Potential unique toxicities to monitor include exacerbation or suppression of tumour-associated inflammation, unforeseen effects on tissue-resident innate cells, and potential additive immune-related adverse events when combined with PD-1/PD-L1 inhibitors. Here, PDCD1 is linked to neoplasm.